Gene info: ID 2068

Gene: ERCC2

GENE ID: 2068

Synonyms: COFS2|EM9|TFIIH|TTD|TTD1|XPD

Description: ERCC excision repair 2, TFIIH core complex helicase subunit

Gene type: protein-coding

Location: 19q13.32

dbXrefs: Ensembl:ENSG00000104884 MIM:126340 Vega:OTTHUMG00000048190 UniprotKB:P18074

RefSeq: NG_007067.2

Retrived from: PubMed

SNPs: 0 ANCO-SNPs

Phenotype: ND

# Publications: 46

Sherlock p-value : NA (AD) NA (ND) (Frontal_Cortex)

Pascal p-value : 1.777e-1 (AD) 5.203e-1 (ND)

DNA Methylation

There is no related methylation information for this gene.

Gene Expression in Different Tissues

Temporal and Spatial Expressions (BrainSpan)

Footnote:
SC: sub-cortical regions; SM: sensory-motor regions; FC: frontal cortex; and TP: temporal-parietal cortex
ST1: fetal (13 - 26 postconception weeks), ST2: early infancy to late childhood (4 months to 11 years), and ST3: adolescence to adulthood (13 - 23 years)
The bar shown representes average value of the expressions.

Top Co-expressed Genes in Brain-Frontal Cortex (BA9) (GTEx v7)

Top 10 positively co-expressed genes

Gene Symbol	Pearson Correlation Coefficient
MEGF8	0.936
GRIK5	0.928
ABR	0.922
ARHGEF4	0.914
NEURL4	0.913
DMWD	0.913
TAOK2	0.91
NAT8L	0.909
C3orf18	0.909
SGSM3	0.909

Top 10 negatively co-expressed genes

Gene Symbol	Pearson Correlation Coefficient
OR4F5	-0.638
OR4F29	-0.574
TFPI2	-0.466
CST7	-0.455
CLEC2B	-0.454
SGMS2	-0.44
IL18RAP	-0.435
KCNJ15	-0.431
S100A12	-0.423
CD48	-0.423

There is no DrugBank record for this gene !

ID	Drug Name	Action	PubMed
C025205	1,10-phenanthroline	"1,10-phenanthroline results in decreased expression of ERCC2 mRNA"	19502547
C111118	2',3,3',4',5-pentachloro-4-hydroxybiphenyl	"2',3,3',4',5-pentachloro-4-hydroxybiphenyl results in decreased expression of ERCC2 mRNA"	19114083
C081510	4-(acetoxymethylnitrosamino)-1-(3-pyridyl)-1-butanone	ERCC2 protein affects the susceptibility to 4-(acetoxymethylnitrosamino)-1-(3-pyridyl)-1-butanone	19601657
C081510	4-(acetoxymethylnitrosamino)-1-(3-pyridyl)-1-butanone	ERCC2 protein affects the susceptibility to [4-(acetoxymethylnitrosamino)-1-(3-pyridyl)-1-butanone results in increased mutagenesis of HPRT1 gene]	19601657
C027576	4-hydroxy-2-nonenal	4-hydroxy-2-nonenal results in decreased expression of ERCC2 mRNA	12419474
D016604	Aflatoxin B1	Aflatoxin B1 results in increased expression of ERCC2 mRNA	26260870
D000395	Air Pollutants, Occupational	"ERCC2 gene polymorphism affects the susceptibility to Air Pollutants, Occupational"	20723587
C004984	apocarotenal	apocarotenal results in decreased expression of ERCC2 mRNA	17034753
D001115	Arecoline	Arecoline results in decreased expression of ERCC2 mRNA	17682004
D001151	Arsenic	Arsenic promotes the reaction [ERCC2 protein binds to and results in decreased activity of CDK7 protein]	24473091
D001151	Arsenic	Arsenic results in decreased methylation of ERCC2 promoter	24473091
D001151	Arsenic	Arsenic results in increased expression of ERCC2 mRNA	11134558
D001151	Arsenic	Arsenic results in increased expression of ERCC2 protein	24473091
D001151	Arsenic	ERCC2 exon SNP results in increased susceptibility to Arsenic	17050553
D001151	Arsenic	ERCC2 gene SNP affects the susceptibility to Arsenic	17470448\|1983468
D001151	Arsenic	ERCC2 gene SNP results in increased susceptibility to Arsenic	12749816
D001151	Arsenic	ERCC2 polymorphism affects the susceptibility to Arsenic	17687452
C006632	arsenic trioxide	arsenic trioxide results in decreased expression of ERCC2 mRNA	22521957
C015001	arsenite	ERCC2 protein affects the susceptibility to arsenite	18602460
C015001	arsenite	ERCC2 protein inhibits the reaction [arsenite results in increased abundance of Hydrogen Peroxide]	18602460
D001205	Ascorbic Acid	[Diethylnitrosamine co-treated with kojic acid co-treated with Ascorbic Acid] results in increased expression of ERCC2 mRNA	17917374
D001280	Atrazine	Atrazine results in increased expression of ERCC2 mRNA	25929836
D001554	Benzene	ERCC2 gene polymorphism results in increased susceptibility to Benzene	16889696
D001564	Benzo(a)pyrene	ERCC2 protein affects the susceptibility to Benzo(a)pyrene	22382310
D001564	Benzo(a)pyrene	Benzo(a)pyrene results in increased expression of ERCC2 mRNA	22641617
D015123	7,8-Dihydro-7,8-dihydroxybenzo(a)pyrene 9,10-oxide	"7,8-Dihydro-7,8-dihydroxybenzo(a)pyrene 9,10-oxide results in decreased expression of ERCC2 mRNA"	20382639
D019207	beta Carotene	beta Carotene results in decreased expression of ERCC2 mRNA	17034753
D004958	Estradiol	Estradiol results in decreased expression of ERCC2 mRNA	16705744
C006780	bisphenol A	bisphenol A affects the expression of ERCC2 mRNA	21786754
C006780	bisphenol A	bisphenol A results in decreased expression of ERCC2 mRNA	29275510
C006780	bisphenol A	bisphenol A affects the expression of ERCC2 mRNA	21786754
D019256	Cadmium Chloride	[sodium arsenite co-treated with Cadmium Chloride co-treated with chromic oxide co-treated with chromous chloride co-treated with lead acetate] results in decreased expression of ERCC2 mRNA	12634122
D000068579	Celecoxib	Celecoxib results in increased expression of ERCC2 mRNA	28201806
C023600	chromic oxide	[sodium arsenite co-treated with Cadmium Chloride co-treated with chromic oxide co-treated with chromous chloride co-treated with lead acetate] results in decreased expression of ERCC2 mRNA	12634122
C017133	chromous chloride	[sodium arsenite co-treated with Cadmium Chloride co-treated with chromic oxide co-treated with chromous chloride co-treated with lead acetate] results in decreased expression of ERCC2 mRNA	12634122
D002994	Clofibrate	Clofibrate results in decreased expression of ERCC2 mRNA	17585979
C018021	cobaltous chloride	cobaltous chloride results in decreased expression of ERCC2 mRNA	19320972
D003520	Cyclophosphamide	Cyclophosphamide affects the expression of ERCC2 mRNA	11906922
D016572	Cyclosporine	Cyclosporine results in increased expression of ERCC2 mRNA	25562108
C017160	cypermethrin	cypermethrin results in decreased expression of ERCC2 mRNA	22528246
D002945	Cisplatin	ERCC2 gene mutant form results in increased susceptibility to Cisplatin	28027876
D002945	Cisplatin	Cisplatin results in decreased expression of ERCC2 mRNA	27594783
D002945	Cisplatin	ERCC2 mRNA results in decreased susceptibility to Cisplatin	15882455
D002945	Cisplatin	ERCC2 protein inhibits the reaction [ERCC2 gene mutant form results in increased susceptibility to Cisplatin]	28027876\|2802787
D002945	Cisplatin	ERCC2 SNP inhibits the reaction [ERCC2 gene mutant form results in increased susceptibility to Cisplatin]	28027876\|2802787
D002945	Cisplatin	[Cisplatin co-treated with Lutein] results in decreased expression of ERCC2 mRNA	24865317
D002945	Cisplatin	Cisplatin results in decreased expression of ERCC2 mRNA	24865317
D004052	Diethylnitrosamine	[Diethylnitrosamine co-treated with kojic acid co-treated with Ascorbic Acid] results in increased expression of ERCC2 mRNA	17917374
D004147	Dioxins	Dioxins affects the expression of ERCC2 mRNA	20463971
D004997	Ethinyl Estradiol	Ethinyl Estradiol results in decreased expression of ERCC2 mRNA	17662478
D005472	Fluorouracil	ERCC2 gene polymorphism affects the susceptibility to [Fluorouracil co-treated with oxaliplatin]	15213713
D005472	Fluorouracil	ERCC2 gene SNP affects the susceptibility to [Fluorouracil co-treated with Leucovorin co-treated with oxaliplatin]	17401013
C410216	Folfox protocol	ERCC2 gene polymorphism results in increased susceptibility to Folfox protocol analog	18505590
D002955	Leucovorin	ERCC2 gene SNP affects the susceptibility to [Fluorouracil co-treated with Leucovorin co-treated with oxaliplatin]	17401013
D019833	Genistein	Genistein results in decreased expression of ERCC2 mRNA	16705744
D006046	Gold	[Polyethyleneimine binds to Gold] which results in decreased expression of ERCC2 mRNA	28433809
D006861	Hydrogen Peroxide	ERCC2 protein inhibits the reaction [arsenite results in increased abundance of Hydrogen Peroxide]	18602460
C056493	imiquimod	imiquimod results in decreased expression of ERCC2 mRNA	21878529
D007213	Indomethacin	Indomethacin results in increased expression of ERCC2 mRNA	28201806
C011890	kojic acid	[Diethylnitrosamine co-treated with kojic acid co-treated with Ascorbic Acid] results in increased expression of ERCC2 mRNA	17917374
D007854	Lead	Lead results in decreased expression of ERCC2 mRNA	19921347
C008261	lead acetate	[sodium arsenite co-treated with Cadmium Chloride co-treated with chromic oxide co-treated with chromous chloride co-treated with lead acetate] results in decreased expression of ERCC2 mRNA	12634122
D014975	Lutein	[Cisplatin co-treated with Lutein] results in decreased expression of ERCC2 mRNA	24865317
D014975	Lutein	Lutein results in decreased expression of ERCC2 mRNA	24865317
D008345	Manganese	Manganese results in increased expression of ERCC2 mRNA	18284614
C406082	monomethylarsonous acid	monomethylarsonous acid results in increased expression of ERCC2 mRNA	22108045
C005246	myristicin	myristicin results in decreased expression of ERCC2 mRNA	24792648
C030110	oxaliplatin	ERCC2 gene polymorphism affects the susceptibility to [Fluorouracil co-treated with oxaliplatin]	15213713
C030110	oxaliplatin	ERCC2 gene SNP affects the susceptibility to [Fluorouracil co-treated with Leucovorin co-treated with oxaliplatin]	17401013
C030110	oxaliplatin	ERCC2 protein affects the susceptibility to oxaliplatin	15655543\|1677320
C030110	oxaliplatin	oxaliplatin results in increased expression of ERCC2 mRNA	16773204
D010575	Pesticides	Pesticides results in decreased methylation of ERCC2 gene	28396702
D017671	Platinum Compounds	ERCC2 affects the susceptibility to Platinum Compounds	21844884
D011094	Polyethyleneimine	[Polyethyleneimine binds to Gold] which results in decreased expression of ERCC2 mRNA	28433809
D011192	Potassium Dichromate	Potassium Dichromate results in decreased expression of ERCC2 protein	23718831
C045362	prochloraz	prochloraz results in increased expression of ERCC2 mRNA	29038839
C012526	quercitrin	quercitrin results in decreased expression of ERCC2 mRNA	25193878
C547185	riccardin D	riccardin D results in decreased expression of ERCC2 mRNA	24069304
D012834	Silver	Silver affects the expression of ERCC2 mRNA	19429238
D012834	Silver	Silver results in decreased expression of ERCC2 mRNA	22576574
C017947	sodium arsenite	[sodium arsenite co-treated with Cadmium Chloride co-treated with chromic oxide co-treated with chromous chloride co-treated with lead acetate] results in decreased expression of ERCC2 mRNA	12634122
C017947	sodium arsenite	sodium arsenite results in decreased expression of ERCC2 mRNA	12760830
D053260	Soot	Soot results in decreased expression of ERCC2 mRNA	21914721
D013629	Tamoxifen	ERCC2 gene SNP results in increased susceptibility to Tamoxifen	24716840
D043823	Taxoids	ERCC2 gene SNP results in increased susceptibility to Taxoids	16981845
D013849	Thimerosal	Thimerosal results in decreased expression of ERCC2 mRNA	27188386
D014212	Tretinoin	Tretinoin results in increased expression of ERCC2 mRNA	23724009
C016805	tris(1,3-dichloro-2-propyl)phosphate	"tris(1,3-dichloro-2-propyl)phosphate results in increased expression of ERCC2 mRNA"	26179874
D014752	Vinyl Chloride	ERCC2 gene SNP results in increased susceptibility to Vinyl Chloride	18420361

GO/Pathway

GO ID	GO Term	Qualifier	Evidence	PubMed
GO:0003677	DNA binding	-	IEA	-
GO:0003684	damaged DNA binding	-	IBA	21873635
GO:0004003	ATP-dependent DNA helicase activity	-	IBA	21873635
GO:0004003	ATP-dependent DNA helicase activity	-	IEA	-
GO:0004672	protein kinase activity	contributes_to	IDA	9852112
GO:0005515	protein binding	-	IPI	7663514 8652557 11445587 16669699 20797633 25416956 27193682 28178521
GO:0005524	ATP binding	-	IEA	-
GO:0008022	protein C-terminus binding	-	IPI	10801852
GO:0008094	DNA-dependent ATPase activity	contributes_to	IDA	9852112
GO:0008094	DNA-dependent ATPase activity	-	TAS	8663148
GO:0008353	RNA polymerase II carboxy-terminal domain kinase activity	CONTRIBUTES_TO	IBA	21873635
GO:0008353	RNA polymerase II carboxy-terminal domain kinase activity	contributes_to	IDA	9852112
GO:0043139	5'-3' DNA helicase activity	-	IDA	8663148 11445587
GO:0043141	ATP-dependent 5'-3' DNA helicase activity	-	IBA	21873635
GO:0046872	metal ion binding	-	IEA	-
GO:0047485	protein N-terminus binding	-	IPI	8652557
GO:0051539	4 iron, 4 sulfur cluster binding	-	IEA	-

GO ID	GO Term	Qualifier	Evidence	PubMed
GO:0000019	regulation of mitotic recombination	-	IBA	21873635
GO:0000717	nucleotide-excision repair, DNA duplex unwinding	-	IBA	21873635
GO:0001666	response to hypoxia	-	IEA	-
GO:0001701	in utero embryonic development	-	IEA	-
GO:0006283	transcription-coupled nucleotide-excision repair	-	IDA	8663148
GO:0006283	transcription-coupled nucleotide-excision repair	-	TAS	-
GO:0006289	nucleotide-excision repair	-	IGI	2835663
GO:0006289	nucleotide-excision repair	-	NAS	2184031
GO:0006293	nucleotide-excision repair, preincision complex stabilization	-	TAS	-
GO:0006294	nucleotide-excision repair, preincision complex assembly	-	TAS	-
GO:0006296	nucleotide-excision repair, DNA incision, 5'-to lesion	-	TAS	-
GO:0006361	transcription initiation from RNA polymerase I promoter	-	TAS	-
GO:0006363	termination of RNA polymerase I transcription	-	TAS	-
GO:0006366	transcription by RNA polymerase II	-	IBA	21873635
GO:0006366	transcription by RNA polymerase II	-	IDA	9852112
GO:0006366	transcription by RNA polymerase II	-	TAS	8663148
GO:0006367	transcription initiation from RNA polymerase II promoter	-	TAS	-
GO:0006368	transcription elongation from RNA polymerase II promoter	-	TAS	-
GO:0006370	7-methylguanosine mRNA capping	-	TAS	-
GO:0006468	protein phosphorylation	-	IEA	-
GO:0006915	apoptotic process	-	IMP	8675009
GO:0006979	response to oxidative stress	-	IBA	21873635
GO:0006979	response to oxidative stress	-	IMP	17614221
GO:0007059	chromosome segregation	-	IMP	20797633
GO:0007568	aging	-	IEA	-
GO:0008283	cell proliferation	-	IEA	-
GO:0009411	response to UV	-	IBA	21873635
GO:0009650	UV protection	-	IGI	2835663
GO:0009791	post-embryonic development	-	IEA	-
GO:0016032	viral process	-	IEA	-
GO:0021510	spinal cord development	-	IEA	-
GO:0030198	extracellular matrix organization	-	IEA	-
GO:0030282	bone mineralization	-	IEA	-
GO:0032289	central nervous system myelin formation	-	IEA	-
GO:0032508	DNA duplex unwinding	-	IEA	-
GO:0033683	nucleotide-excision repair, DNA incision	-	IBA	21873635
GO:0033683	nucleotide-excision repair, DNA incision	-	IMP	8692841
GO:0033683	nucleotide-excision repair, DNA incision	-	TAS	-
GO:0035264	multicellular organism growth	-	IEA	-
GO:0035315	hair cell differentiation	-	IMP	11335038
GO:0040016	embryonic cleavage	-	IEA	-
GO:0043249	erythrocyte maturation	-	IEA	-
GO:0043388	positive regulation of DNA binding	-	IEA	-
GO:0045893	positive regulation of transcription, DNA-templated	-	IBA	21873635
GO:0045893	positive regulation of transcription, DNA-templated	-	IDA	8692842
GO:0045944	positive regulation of transcription by RNA polymerase II	-	IDA	8692841
GO:0045951	positive regulation of mitotic recombination	-	IBA	21873635
GO:0048568	embryonic organ development	-	IEA	-
GO:0048820	hair follicle maturation	-	IEA	-
GO:0060218	hematopoietic stem cell differentiation	-	IEA	-
GO:0070911	global genome nucleotide-excision repair	-	TAS	-
GO:1901990	regulation of mitotic cell cycle phase transition	-	IMP	17088560

GO ID	GO Term	Qualifier	Evidence	PubMed
GO:0000439	core TFIIH complex	-	IEA	-
GO:0005634	nucleus	-	IBA	21873635
GO:0005634	nucleus	-	IDA	20797633
GO:0005654	nucleoplasm	-	IDA	-
GO:0005654	nucleoplasm	-	TAS	-
GO:0005669	transcription factor TFIID complex	-	IDA	27193682
GO:0005675	holo TFIIH complex	-	IDA	9852112
GO:0005675	holo TFIIH complex	-	TAS	7663514
GO:0005737	cytoplasm	-	IDA	20797633
GO:0005819	spindle	-	IDA	20797633
GO:0005829	cytosol	-	IDA	-
GO:0019907	cyclin-dependent protein kinase activating kinase holoenzyme complex	colocalizes_with	IDA	8692842 11445587
GO:0071817	MMXD complex	-	IDA	20797633

KEGG ID	KEGG Term
hsa03420	Nucleotide excision repair

Reactome ID	Reactome Term	Evidence
R-HSA-112382	Formation of RNA Pol II elongation complex	TAS
R-HSA-113418	Formation of the Early Elongation Complex	TAS
R-HSA-1430728	Metabolism	IEA
R-HSA-162587	HIV Life Cycle	IEA
R-HSA-162599	Late Phase of HIV Life Cycle	IEA
R-HSA-162906	HIV Infection	IEA
R-HSA-1643685	Disease	IEA
R-HSA-167152	Formation of HIV elongation complex in the absence of HIV Tat	IEA
R-HSA-167158	Formation of the HIV-1 Early Elongation Complex	IEA
R-HSA-167160	RNA Pol II CTD phosphorylation and interaction with CE during HIV infection	IEA
R-HSA-167161	HIV Transcription Initiation	IEA
R-HSA-167162	RNA Polymerase II HIV Promoter Escape	IEA
R-HSA-167169	HIV Transcription Elongation	IEA
R-HSA-167172	Transcription of the HIV genome	IEA
R-HSA-167200	Formation of HIV-1 elongation complex containing HIV-1 Tat	IEA
R-HSA-167246	Tat-mediated elongation of the HIV-1 transcript	IEA
R-HSA-212165	Epigenetic regulation of gene expression	IEA
R-HSA-212436	Generic Transcription Pathway	TAS
R-HSA-2564830	Cytosolic iron-sulfur cluster assembly	IEA
R-HSA-3700989	Transcriptional Regulation by TP53	TAS
R-HSA-427413	NoRC negatively regulates rRNA expression	IEA
R-HSA-5250941	Negative epigenetic regulation of rRNA expression	IEA
R-HSA-5663205	Infectious disease	IEA
R-HSA-5696395	Formation of Incision Complex in GG-NER	TAS
R-HSA-5696398	Nucleotide Excision Repair	TAS
R-HSA-5696399	Global Genome Nucleotide Excision Repair (GG-NER)	TAS
R-HSA-5696400	Dual Incision in GG-NER	TAS
R-HSA-674695	RNA Polymerase II Pre-transcription Events	TAS
R-HSA-6781823	Formation of TC-NER Pre-Incision Complex	TAS
R-HSA-6781827	Transcription-Coupled Nucleotide Excision Repair (TC-NER)	TAS
R-HSA-6782135	Dual incision in TC-NER	TAS
R-HSA-6782210	Gap-filling DNA repair synthesis and ligation in TC-NER	TAS
R-HSA-6796648	TP53 Regulates Transcription of DNA Repair Genes	TAS
R-HSA-72086	mRNA Capping	TAS
R-HSA-73762	RNA Polymerase I Transcription Initiation	TAS
R-HSA-73772	RNA Polymerase I Promoter Escape	TAS
R-HSA-73776	RNA Polymerase II Promoter Escape	TAS
R-HSA-73777	RNA Polymerase I Chain Elongation	TAS
R-HSA-73779	RNA Polymerase II Transcription Pre-Initiation And Promoter Opening	TAS
R-HSA-73854	RNA Polymerase I Promoter Clearance	TAS
R-HSA-73857	RNA Polymerase II Transcription	TAS
R-HSA-73863	RNA Polymerase I Transcription Termination	TAS
R-HSA-73864	RNA Polymerase I Transcription	TAS
R-HSA-73894	DNA Repair	TAS
R-HSA-74160	Gene expression (Transcription)	TAS
R-HSA-74160	Gene expression (Transcription)	IEA
R-HSA-75953	RNA Polymerase II Transcription Initiation	TAS
R-HSA-75955	RNA Polymerase II Transcription Elongation	TAS
R-HSA-76042	RNA Polymerase II Transcription Initiation And Promoter Clearance	TAS
R-HSA-77075	RNA Pol II CTD phosphorylation and interaction with CE	TAS
R-HSA-8953854	Metabolism of RNA	TAS

Interactions (STRING v10.5, Interaction Score >= 0.400)

Publications (Co-occurrence of gene symbol strings and ANCO-Dependence terms)

PMID	Title (Year)	Author	Journal
16537713	Genetic variation in the nucleotide excision repair pathway and bladder cancer risk. (2006 Mar)	Garcia-Closas M	Cancer Epidemiol Biomarkers Prev
27668351	Study of association between pre-senile cataracts and rs11615 of ERCC1, rs13181 of ERCC2, and rs25487 of XRCC1 polymorphisms in a Spanish population. (2017 Jul-Aug)	Lopez-Valverde G	Ophthalmic Genet
11133811	XPD/ERCC2 polymorphisms and risk of head and neck cancer: a case-control analysis. (2000 Dec)	Sturgis EM	Carcinogenesis
28664594	Evaluation of baseline frequency of sister chromatid exchanges in an Italian population according to age, sex, smoking habits, and gene polymorphisms. (2017 Nov)	Santovito A	Am J Hum Biol
27183913	Fine-mapping markers of lung cancer susceptibility in a sub-region of chromosome 19q13.3 among Chinese. (2016 Sep 20)	Yin J	Oncotarget
21195504	Association of genetic polymorphisms in DNA repair pathway genes with non-small cell lung cancer risk. (2011 Aug)	Qian B	Lung Cancer
25400036	DNA repair gene polymorphisms in B cell non-Hodgkin's lymphoma. (2015 Mar)	Bahceci A	Tumour Biol
24020925	DNA repair gene polymorphisms and risk of head and neck cancer in the Tunisian population. (2014 Mar)	Khlifi R	J Oral Pathol Med
18075460	Single nucleotide polymorphisms of the DNA repair gene XPD/ERCC2 alter mRNA expression. (2007 Nov)	Wolfe KJ	Pharmacogenet Genomics
12110342	XPD/ERCC2 EXON 8 Polymorphisms: rarity and lack of significance in risk of squamous cell carcinoma of the head and neck. (2002 Jul)	Sturgis EM	Oral Oncol
24140460	HapMap-based study identifies risk sub-region on chromosome 19q13.3 in relation to lung cancer among Chinese. (2013 Dec)	Yin J	Cancer Epidemiol
19902366	Genetic variation in DNA repair genes and prostate cancer risk: results from a population-based study. (2010 Feb)	Agalliu I	Cancer Causes Control
16806437	Nucleotide excision repair genotype and the incidence of endometrial cancer: effect of other risk factors on the association. (2006 Dec)	Weiss JM	Gynecol Oncol
24582975	Laryngeal cancer risk and common single nucleotide polymorphisms in nucleotide excision repair pathway genes ERCC1, ERCC2, ERCC3, ERCC4, ERCC5 and XPA. (2014 May 25)	Lu B	Gene
23108145	Genome-wide association study reveals novel genetic determinants of DNA repair capacity in lung cancer. (2013 Jan 1)	Wang LE	Cancer Res
15199549	Polymorphisms in DNA repair genes, chromosome aberrations, and lung cancer. (2004)	Harms C	Environ Mol Mutagen
12435843	ERCC2/XPD gene polymorphisms and cancer risk. (2002 Nov)	Benhamou S	Mutagenesis
22740911	Single nucleotide polymorphisms in DNA repair genes and risk of cervical cancer: A case-control study. (2012 Feb)	Zhang L	Oncol Lett
16824555	Influence of DNA repair polymorphisms on biomarkers of genotoxic damage in peripheral lymphocytes of healthy subjects. (2006 Aug 30)	Zijno A	Mutat Res
26159902	DNA Repair Gene Polymorphisms in Relation to Non-Small Cell Lung Cancer Survival. (2015)	Su Y	Cell Physiol Biochem
19444904	Laryngeal cancer risk associated with smoking and alcohol consumption is modified by genetic polymorphisms in ERCC5, ERCC6 and RAD23B but not by polymorphisms in five other nucleotide excision repair genes. (2009 Sep 15)	Abbasi R	Int J Cancer
22277767	Polymorphisms of DNA repair pathway genes and cigarette smoking in relation to susceptibility to large artery atherosclerotic stroke among ethnic Chinese in Taiwan. (2012)	Shyu HY	J Atheroscler Thromb
16492913	Variation in DNA repair genes ERCC2, XRCC1, and XRCC3 and risk of follicular lymphoma. (2006 Feb)	Smedby KE	Cancer Epidemiol Biomarkers Prev
25209371	Potentially functional polymorphisms in the ERCC2 gene and risk of esophageal squamous cell carcinoma in Chinese populations. (2014 Sep 11)	Zhu ML	Sci Rep
26617899	Association of NER pathway gene polymorphisms with susceptibility to laryngeal cancer in a Chinese population. (2015)	Sun Y	Int J Clin Exp Pathol
12692111	Polymorphisms in the DNA repair genes XRCC1 and ERCC2, smoking, and lung cancer risk. (2003 Apr)	Zhou W	Cancer Epidemiol Biomarkers Prev
17896209	PAH-DNA adducts in a Chinese population: relationship to PAH exposure, smoking and polymorphisms of metabolic and DNA repair genes. (2008 Feb)	Hu Y	Biomarkers
24933103	Associations of polymorphisms in DNA repair genes and MDR1 gene with chemotherapy response and survival of non-small cell lung cancer. (2014)	Du Y	PLoS One
24834240	Relationship between XPD Lys 751 Gln polymorphism and colorectal cancer risk: a case-control study in a population-based study. (2013 Winter)	Rezaei H	Gastroenterol Hepatol Bed Bench
16492920	Nucleotide excision repair gene polymorphisms and risk of advanced colorectal adenoma: XPC polymorphisms modify smoking-related risk. (2006 Feb)	Huang WY	Cancer Epidemiol Biomarkers Prev
18196582	Polymorphisms in XPC and ERCC2 genes, smoking and breast cancer risk. (2008 May 1)	Shore RE	Int J Cancer
20003463	Association between polymorphisms in DNA repair genes and survival of non-smoking female patients with lung adenocarcinoma. (2009 Dec 15)	Yin Z	BMC Cancer
18709642	Nucleotide excision repair genes and risk of lung cancer among San Francisco Bay Area Latinos and African Americans. (2008 Nov 1)	Chang JS	Int J Cancer
15615908	ERCC2 /XPD gene polymorphisms and lung cancer: a HuGE review. (2005 Jan 1)	Benhamou S	Am J Epidemiol
14568296	Effects of ALDH2 gene polymorphisms and alcohol-drinking behavior on micronuclei frequency in non-smokers. (2003 Nov 10)	Ishikawa H	Mutat Res
23147699	Association of genetic polymorphisms in ERCC1 and ERCC2/XPD with risk of chronic benzene poisoning in a Chinese occupational population. (2013 Feb 18)	Xiao S	Mutat Res
23435956	Decreased expression of DNA repair genes (XRCC1, ERCC1, ERCC2, and ERCC4) in squamous intraepithelial lesion and invasive squamous cell carcinoma of the cervix. (2013 May)	Bajpai D	Mol Cell Biochem
24504678	Complex association between ERCC2 gene polymorphisms, gender, smoking and the susceptibility to bladder cancer: a meta-analysis. (2014 Jun)	Wu Y	Tumour Biol
21601580	HapMap-based study of a region encompassing ERCC1 and ERCC2 related to lung cancer susceptibility in a Chinese population. (2011 Aug 1)	Yin J	Mutat Res
20627704	ERCC2 Lys751Gln polymorphism is associated with lung cancer among Caucasians. (2010 Sep)	Zhang J	Eur J Cancer
20003391	ERCC2, ERCC1 polymorphisms and haplotypes, cooking oil fume and lung adenocarcinoma risk in Chinese non-smoking females. (2009 Dec 14)	Yin Z	J Exp Clin Cancer Res
24084248	The GSTM1null (deletion) and MGMT84 rs12917 (Phe/Phe) haplotype are associated with bulky DNA adduct levels in human leukocytes. (2013 Dec 12)	Molina E	Mutat Res
20651612	ERCC2/XPD Lys751Gln and Asp312Asn gene polymorphism and lung cancer risk: a meta-analysis involving 22 case-control studies. (2010 Sep)	Zhan P	J Thorac Oncol
18544627	Polymorphisms in DNA repair genes, smoking, and pancreatic adenocarcinoma risk. (2008 Jun 15)	McWilliams RR	Cancer Res
11888908	Gene-environment interaction for the ERCC2 polymorphisms and cumulative cigarette smoking exposure in lung cancer. (2002 Mar 1)	Zhou W	Cancer Res
15199548	Effect of XPD/ERCC2 polymorphisms on chromosome aberration frequencies in smokers and on sensitivity to the mutagenic tobacco-specific nitrosamine NNK. (2004)	Affatato AA	Environ Mol Mutagen